A high-affinity ErbB4Fc fusion protein is a potent antagonist of heregulin-mediated receptor activation
Eva J Koziolek, Jacqueline F Donoghue, John D Bentley, George Lovrecz, Olan Dolezal, Colin W Ward, Julie Rothacker, Edouard C Nice, Antony W Burgess, M Hafner, Terrance G Johns, Timothy E Adams
GROWTH FACTORS | INFORMA HEALTHCARE | Published : 2012
The work was partially funded by the Daimler and Benz Foundation, Ladenburg, Germany and Aventis Foundation, Frankfurt, Germany. Terrance Johns is a Clinical Research Fellow for the Victorian Cancer Agency. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.